Although the production of pituitary hormones by adenohypophysial tumors has been studied extensively, an examination of the immunophenotype of pituitary adenomas using a broad spectrum of antibodies has not been previously investigated. We studied 23 pituitary adenomas using a large panel of antibodies to determine if these tumors exhibited a common immunophenotype. Various neuroendocrine markers, synaptophysin, neuron-specific enolase (NSE), and the intermediate filament protein, low-mol-wt keratin were expressed in most examples. There was, however, differential expression of chromogranin A in that few prolactin (PRL) and adenocorticotrophic hormone (ACTH) adenomas stained positively, whereas all other adenoma subtypes were reactive. The ACTH adenomas had a unique profile with positive staining for galanin, neurophysiri, vasopressin, and ubiquitin. These results indicate that (1) pituitary adenomas do not express a single "generic" immunophenotype; (2) synaptophysin is the most reliable and best broad spectrum marker for pituitary adenomas; (3) the neuroendocrine granule marker chromogranin A is useful in the identification of null cell adenoma, a tumor that usually does not stain for anterior pituitary tumors; and (4) among pituitary tumors, ACTH adenomas have a unique immunoprofile.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF02739974 | DOI Listing |
Int J Mol Sci
January 2025
Department of Neurosurgery, Odense University Hospital, DK-5000 Odense, Denmark.
Pituitary adenomas are a diverse group of neoplasms with variable clinical behavior. Despite advances in genetic analysis, understanding the role of epigenetic modifications, particularly DNA methylation, remains an area under investigation. This scoping review aimed to update and synthesize the current body of literature on DNA methylation in pituitary adenomas, focusing on methodological advancements and clinical correlations.
View Article and Find Full Text PDFWorld Neurosurg
January 2025
Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, China. Electronic address:
Objective: To summarize the clinical characteristics, pituitary function assessment, postoperative pathological features, and postoperative recurrence of surgically treated pituitary adenomas (PAs).
Methods: We retrospectively reviewed the data of 338 patients (169 women; average age: 50.01 ± 12.
Neurol Int
January 2025
Department of Neurosurgery, University of Ulm, Lindenallee 2, 89312 Günzburg, Germany.
Background: Endoscopic pituitary surgery might yield better endocrine outcomes compared to microscopic resection. We conducted a prospective, randomized, single-blinded study to compare the endocrine outcome and quality of life (QoL) of patients with newly diagnosed pituitary adenoma who underwent either endoscopic or microscopic transsphenoidal surgery (NCT03515603).
Methods: Due to slow recruitment, this study had to be stopped prematurely.
J Clin Res Pediatr Endocrinol
January 2025
Department of Pediatric Endocrinology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Prolactinomas are the most common hormone-secreting pituitary adenomas in adolescents. Dopamine agonists (DA) are used as first-line medical treatment. DAs are associated with an array of physical side effects; however, impulse control disorders (ICDs), such as pathological gambling (PG), have also been reported in adults.
View Article and Find Full Text PDFBackground: Hypothyroidism is a common sequela after radiotherapy for nasopharyngeal carcinoma (NPC). Magnetic resonance imaging (MRI) has gained prominence in thyroid imaging, leveraging its non-ionizing radiation, high spatial resolution, multiparameter and multidirectional imaging. Few previous studies have investigated the evaluation of radiation-induced thyroid injury by MRI.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!